CZL-077

Overview

CZL-077 is a potent, selective, and orally active p300/CBP bromodomain (BRD) inhibitor ( p300 IC 50 = 0.034 μM, CBP IC 50 = 0.052 μM) exhibiting high selectivity over the BRDs of BET proteins ( BRD2/3/4 ). CZL-077 inhibits cell growth with IC 50 values of 0.024 μM and 5.6 μM in OPM-2 and 22RV1 cells, respectively. CZL-077 shows antitumor efficacy in OPM-2 and 22RV1 xenograft mouse models. CZL-077 can be used for multiple myeloma and prostate cancer research.

Application

Products | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Blood Disease | Products > Disease Areas > Multiple Myeloma | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Prostate Cancer | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Histone Acetyltransferase | Products > Signaling Pathways > Epigenetic Reader Domain

Product Information

• Catalog No.: HY-180804
• CAS No.: 3032444-06-4
• Molecular Formula: C30H26F3N5O2S
• Molecular Weight: 577.62
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source